• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Congress considers sweeping changes to False Claims Act

Article

The civil False Claims Act is the principal weapon in the government's arsenal to combat healthcare fraud. The Senate and the House are considering bills that would further expand the scope of liability under the Act and eliminate two of the key defenses to meritless lawsuits filed by qui tam plaintiffs.

• First, the bills would expand liability to situations where companies submit claims for payment to private entities that have received government funds, such as universities and laboratories that have received federal grants. These situations are currently governed by state tort and contract laws, not the False Claims Act. This expansion would threaten to transform the Act into an all-purpose anti-fraud statute.

• The bills would expand liability to situations where companies knowingly retain government overpayments. As drafted, the bills are very unclear and could impose liability for overpayments that are retained pending a routine reconciliation process.

• Both bills would virtually eliminate the Act's "public disclosure" bar that safeguards against parasitic qui tam lawsuits based on public information. The bills would narrow the scope of the public disclosure bar, and would provide that only the Department of Justice (DOJ), not defendants, could raise this defense. Because the DOJ has neither the resources nor incentive to raise the defense, the practical effect would be a flood of new qui tam lawsuits based on public information.

• The bills would extend the six-year statute of limitations to 10 years. This would increase the potential liability in many actions, and it would also encourage relators to delay filing their claims in order to maximize the government's financial loss and thereby increase their own recovery. It would also impose increased record-keeping costs on every entity doing business with the government, since most records would need to be retained for at least 10 years.

• Finally, both bills would permit current and former government employees to file qui tam actions and thereby use information learned in government service for their own personal gain. The DOJ vehemently opposes this provision, on the ground that it would create conflicts of interest within the federal workforce and undermine public trust in government. For example, government auditors or other personnel that receive a voluntary disclosure would have an incentive to file a qui tam lawsuit based on the information they receive.

The net effect of these proposed changes would not be to assist the DOJ in its fight against fraud on the federal Treasury, but to assist qui tam plaintiffs in bringing unfounded actions to benefit themselves and their lawyers. There is bipartisan support for both bills, and there is a real possibility that many or all of the provisions in the current bills will eventually become law.

Peter B. Hutt, II, is a partner in the Washington, D.C., office of law firm Akin Gump Strauss Hauer & Feld LLP.

This column is written for informational purposes only and should not be construed as legal advice.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.